Briefing
Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck
A tumor-agnostic plasma ctDNA assay detected MRD after curative-intent treatment in locally advanced SCCHN and stratified 2-year PFS (23.5% if MRD-positive vs 86.6% if MRD-negative).
- Design: Evidence level 3
- Assay: Not named in the abstract